IJPR  articles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 0.13 (2013 - 2018).    

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

ISSN
0975-2366
5 - Years Impact Factor

Year 2012 - 2016

Impact Factor: 1.55

Total Publications: 317

Total Citation: 491

Year 2011 - 2015

Impact Factor: 1.46

Total Publications: 326

Total Citation: 477

Year 2010 - 2014

Impact Factor: 1.3

Total Publications: 313

Total Citation: 407

Year 2009 - 2013

Impact Factor: 0.973

Total Publications: 293

Total Citation: 285

Current Issue
22nd NATIONAL CONVENTION

22nd National Convention of Society of Pharmacognosy & International Conference. For more details visit


For More Detail Visit ncsp.ganpatuniversity.ac.in
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPRT ISSUE

January - March 6 [1] 2014

Click to download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
BRINZOLAMIDE-2-HYDROXYPROPYL BETA CYCLODEXTRIN COMPLEX LOADED CHITOSAN NANOGEL FOR OCULAR DRUG DELIVERY

Author: DHANAJA PILLAI, SABITHA M, SWATI GUPTA
Abstract: In this study an inclusion complex between Brinzolamide (BRZ) and 2- Hydroxypropyl Beta Cyclodextrin (2-HP-ß- CD) was prepared and incorporated into Chitosan (CS)/Tripolyphosphate (TPP) nanogels to provide sustained release of BRZ with increased retention time in the corneal region. Further to this, an attempt was made to increase the viscosity of the prepared CS/TPP nanogels using CS/PVA (polyvinyl alcohol) biopolymer composite. BRZ, is a second line therapy for glaucoma but suffers from poor aqueous solubility leading to lesser absorption and side effects on its administration in ocular delivery. Thus by increasing the solubility and ocular retention will reduce its frequency of administration and dose followed by increases its absorption.BRZ was complexed with 2-HP-ß-CD by solvent evaporation and confirmed by FTIR, XRD and SEM. The complex was incorporated into chitosan nanogels and evaluated for in vitro drug release, ex vivo mucoadhesive and permeation studies.BRZ-2-HP-ß-CD complex (1:1 molar ratio) showed improved aqueous solubility and dissolution as compared to BRZ aqueous dispersion. Chitosan nanogels showed particle size of 219.1 ± 0.94 nm, zeta potential of +26.63 ± 0.28 mV, entrapment efficiency of 80.2837 ± 1.7635% having sustained release and following Fickian diffusion. CDNG1 exhibited 15.32 fold increases in the in vitro corneal permeability coefficient in comparison with commercial Brinolar® and exhibited mucoadhesive properties.The results imply the potential of BRZ-HP-ß-CD complex loaded Chitosan Nanogels as a novel formulation of BRZ for ocular delivery
Keyword: Brinzolamide, 2- Hydroxypropyl Beta Cyclodextrin, Chitosan Nanogels, Mucoadhesive, Ocular delivery
Download: Request For Article
 












ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
Pharmacovigilance: Current Scenario and Emerging Trends

National Conference sponsored by GUJCOST on 03.08.2019 at SNLPCP, Umrakh

Download Brochure
News & Events
0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free
0.07
2017CiteScore
 
11th percentile
Powered by  Scopus
Impact Factor for five years is 1.55 (2012 - 2016)

Year 2011 - 2015 Impact Factor - 1.46 Total Publications - 326 Total Citations - 477